Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model

Transplantation

Volumn 85, Issue 5, 2008, Pages 739-747

  Heller, Tanja ^a   Geide, Anna ^a   Bonitz, Ulrike ^a   Wegner, Ulrike ^a   Gröne, Hermann Josef ^b   Armstrong, Victor W ^a   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Gene expression; Idebenone; Mycophenolic acid

Indexed keywords

CATALASE; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; IDEBENONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GENE CONTROL; GENE EXPRESSION; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SYMPTOMATOLOGY;

ANIMALS; ANTIOXIDANTS; CATALASE; COLON; DNA, COMPLEMENTARY; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION; HEMOGLOBINS; IMMUNOSUPPRESSIVE AGENTS; JEJUNUM; MODELS, ANIMAL; MYCOPHENOLIC ACID; RATS; RATS, WISTAR; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUINONE;

EID: 40849114655     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181664e54     Document Type: Article

References (36)

1. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: Focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005; 1: 505.
2. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076.
3. McMurray RW, Harisdangkul V. Mycophenolate mofetil: Selective T cell inhibition. Am J Med Sci 2002; 323: 194.
4. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029.
5. Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K. Crohn's-like changes in the colon due to mycophenolate? Colorectal Dis 2005; 7: 27.
6. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237.
7. Meier-Kriesche HU, Davies NM, Grinyo J, et al. Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant 2005; 5: 1164.
8. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665.
9. Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Broe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol 2003; 60: 119.
10. Arbeiter K, Greenbaum L, Balzar E, et al. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol 2000; 14: 195.
11. van Besouw NM, van der Mast BJ, Smak Gregoor PJ, et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999; 14: 2710.
12. Vanrenterghem Y. Anaemia after renal transplantation. Nephrol Dial Transplant 2004; 19(suppl 5): V54.
13. Shipkova M, Spielbauer B, Voland A, et al. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation 2004; 78: 1145.
14. Hassan A, Martin E, Puig-Parellada P. Role of antioxidants in gastric mucosal damage induced by indomethacin in rats. Methods Find Exp Clin Pharmacol 1998; 20: 849.
15. Sundaram U, Hassanain H, Suntres Z, et al. Rabbit chronic ileitis leads to up-regulation of adenosine A1/A3 gene products, oxidative stress, and immune modulation. Biochem Pharmacol 2003; 65: 1529.
16. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol 1999; 57: 231.
17. Shipkova M, Beck H, Voland A, et al. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 2004; 4: 2728.
18. Miyamoto M, Coyle JT. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins. Exp Neurol 1990; 108: 38.
19. Artuch R, Colome C, Vilaseca MA, Aracil A, Pineda M. Monitoring of idebenone treatment in patients with Friedreich's ataxia by high-pressure liquid chromatography with electrochemical detection. J Neurosci Methods 2002; 115: 63.
20. Rustin P, Rotig A, Munnich A, Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 2002; 36: 467.
21. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: A randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878.
22. Kiyota Y, Miyamoto M, Nagaoka A. Protective effect of idebenone against hypoxia in mice. Arch Gerontol Geriatr 1989; 8: 241.
23. Nagaoka A, Suno M, Shibota M, Kakihana M. Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia. Arch Gerontol Geriatr 1989; 8: 193.
24. Semsei I, Cutler RG, Nagy I. The effects of idebenone on DNA and RNA contents as well as synthesis rates of total and poly(A)+ RNA in brain of normal, old C57BL/6J mice and in experimental partial cerebral ischemia of rats. Arch Gerontol Geriatr 1990; 11: 293.
25. Suno M, Shibota M, Nagaoka A. Effects of idebenone on lipid peroxidation and hemolysis in erythrocytes of stroke-prone spontaneously hypertensive rats. Arch Gerontol Geriatr 1989; 8: 307.
26. Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004; 13: 1017.
27. Streit F, Shipkova M, Armstrong VW, Oellerich M. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic Acid. Clin Chem 2004; 50: 152.
28. Vilaseca J, Salas A, Guarner F, Rodriguez R, Martinez M, Malagelada JR. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990; 31: 539.
29. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004; 9(suppl 5): 18.
30. Lappin T. The cellular biology of erythropoietin receptors. Oncologist 2003; 8(suppl 1): 15.
31. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects? Clin Biochem 2000; 33: 107.
32. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: A graft-versus-host disease-like pattern. Int J Surg Pathol 2003; 11: 295.
33. Neumcke I, Schneider B, Fandrey J, Pagel H. Effects of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology 1999; 140: 641.
34. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993; 696: 63.
35. Nagai M, Natsumeda Y, Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 1992; 52: 258.
36. Yu J, Lemas V, Page T, Connor JD, Yu AL. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Res 1989; 49: 5555.